Stine Hasling Mogensen re-elected as chair of Pharmadanmark

Stine Hasling Mogensen will continue as chair of Pharmadanmark after being re-elected unopposed.

The election took place at Pharmadanmark’s annual Representative Assembly this Saturday.

“I’m proud to continue leading a union that carries out the most important task – being there for our members when they need us the most,” Stine said.

In her report, Stine emphasized how Pharmadanmark has supported members affected by recent mass layoffs in the sector – especially at Novo Nordisk – and underlined the strength of the life science community in a rapidly changing world.

The industry is evolving faster than ever. New technologies, data use, and sustainability demands are reshaping the workplace, while employee wellbeing and public research conditions are under pressure. Stine highlighted that there are still many battles to fight – both collectively and individually – to protect and strengthen members’ rights.

“I’m proud to continue leading a union that carries out the most important task – being there for our members when they need us the most.”

Pharmadanmark is also preparing for a more digital future, with faster, more personal, and flexible member services. Initiatives such as a new membership system and website are already underway.

A new political strategy

Members approved Pharmadanmark’s new political strategy, which outlines the union’s direction through 2029. The strategy builds on extensive member input gathered over the past year through workshops, section meetings, and member events.

The goal is clear: To create better study and working conditions for our members and ensure that Denmark’s life science sector continues to attract and retain the right skills – while employees remain a key priority.

Pharmadanmark will work toward:

• World-class education
• An inclusive labour market
• Strong framework conditions for life science
• A sustainable healthcare system

Spotlight on AMR and rare diseases

The afternoon began with a presentation on Pharmadanmark’s work in the AMR Alliance and the results achieved within the framework of the alliance.

Next, the results of a survey mapping public awareness of antimicrobial resistance were presented. This was followed by the introduction of a new antibiotic resistance campaign, which will run over the coming years. The campaign is coordinated in close collaboration between Associate Professor Patrick Munk from DTU, the communications agency KOMPAS, and the AMR Alliance.

The meeting concluded with a session on rare diseases, featuring insights from:

• Sebastian Honoré, CEO and Founder, Cure Lowe Foundation
• Professor Allan M. Lund, MD, Head of Center for Congenital Metabolic Disorders, Rigshospitalet
• Kirsten Kiær Ahring, Clinical Dietitian, PhD in Human Nutrition, Rigshospitalet
• Jannick Brennum, Vice-Chair, Danish Medicines Council

The speakers joined a panel discussion on strengthening research, diagnosis, and treatment for rare diseases, ensuring access to innovative therapies, and improving conditions for patients and families.

The event ended with a social dinner for all representatives – celebrating another year of collaboration and progress in the life science community.